Gilead may soon be bringing a new cocktail of HIV drugs to market. The company said Monday that a combination of two drugs achieved non-inferiority

Aviceda Therapeutics is pushing forward with Phase 3 plans for its experimental eye drug despite failing a Phase 2b study in geographic atrophy. The mid-stage

Palvella Therapeutics said its drug candidate for a rare skin disease that affects children has yielded positive results in a mid-stage trial. The biotech’s gel

Kyverna Therapeutics’ CAR-T therapy succeeded in a key study in stiff person syndrome, a rare autoimmune disorder that leads to painful muscle spasms and stiffness.

Areteia Therapeutics, one of the biotech industry’s biggest recent startup bets in respiratory illness, has decided to wind down, according to a source familiar with